Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Cyclacel Pharma (CYCC) Misses Q4 EPS by 83c
February 25, 2021 5:19 PM ESTCyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($1.34), $0.83 worse than the analyst estimate of ($0.51).
During 2020 we have reported on fadraciclibs oral bioavailability and evidence of durable anticancer activity, said Spiro Rombotis, President and Chief Executive Officer. Independent evidence supporting the rationale for... More
